Early detection of lung cancer biomarkers through biosensor technology: a review
This article systematically provides a brief overview of various biosensing platforms for identification of lung cancer disease biomarkers, with a specific focus on recent advancements in electrochemical and optical biosensors, analytical performances of different biosensors, challenges and further research opportunities for routine clinical analysis.Graphical abstract
ConclusionTaken together, circRNAs have potential as biomarkers for the diagnosis, prognosis, and treatment of non-small cell lung cancer.
ConclusionsThis study demonstrates an important morphologic, karyotypic and phenotypic CTCs heterogeneity in advanced lung cancer patients. The majority of Vim+ CTCs are in small size and Chr8 aneuploidy. Baseline presence of Vim+ CTCs is correlated with liver metastases and may help predict poor PFS.
ConclusionNon-US and single systemic therapy studies are more commonly associated with strict exclusion of brain metastasis in ES-SCLC trials. The strict exclusion of brain metastases in clinical trials has remained relatively constant for the past few decades.
ConclusionsOur results suggested that CL-pVAX-miR-143 might be a promising strategy for clinical treatment of non-small cell lung cancer, especially for advanced NSCLC with metastasis.
In 60 - year follow - up, significantly lower lung cancer rates seen for those with childhood BCG vaccination
ConclusionsThe effect of therapy directed toward EGFR mutation or EML4 –ALK fusion gene might obscure the significant prognostic difference between M1b and M1c.
Four cancer centers are joining forces on a new clinical trial designed to test medically tailored meals for patients with lung cancer to combat malnutrition.
Sophie Sabbage, pictured with her daughter Gabriella, smoked ten cigarettes a day for a decade, but after quitting for good in the 1990s, she was diagnosed with terminal lung cancer.
antovani The CCAAT box is recognized by the trimeric transcription factor NF-Y, whose NF-YA subunit is present in two major splicing isoforms, NF-YAl (“long”) and NF-YAs (“short”). Little is known about the expression levels of NF-Y subunits in tumors, and nothing in lung cancer. By interrogating RNA-seq TCGA and GEO datasets, we found that, unlike NF-YB/NF-YC, NF-YAs is overexpressed in lung squamous cell carcinomas (LUSC). The ratio of the two isoforms changes from normal to cancer cells, with NF-YAs becoming predominant in the latter. NF-YA increased expression correlates with...